Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Mar;33(3):261–267. doi: 10.1111/j.1365-2125.1992.tb04033.x

A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.

G J Macphee 1, C A Howie 1, H L Elliott 1, J L Reid 1
PMCID: PMC1381273  PMID: 1576046

Abstract

1. This randomised double-blind placebo controlled crossover study in healthy normotensive males compared the haemodynamic and behavioural responses following single oral doses of moxonidine (200 micrograms), clonidine (200 micrograms) and placebo. 2. Both active drugs significantly reduced blood pressure as compared with placebo: on average (over the study day) by -5.6/-0.8 with moxonidine and by -13.3/-5.3 mm Hg with clonidine. The hypotensive effect of clonidine was significantly greater (95% CI 3.2-12.2). Heart rate was unchanged by either drug. 3. Psychomotor testing, salivary flow and side effect reporting showed a consistent treatment rank order similar to that of the hypotensive response: clonidine greater than moxonidine greater than placebo. 4. Although moxonidine produced less adverse effects than clonidine, an equivalent hypotensive response was not demonstrated in normal subjects. Further study at comparable antihypertensive doses is required to clarify the relative side effect profile of these agents.

Full text

PDF
261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armah B. I., Hofferber E., Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforschung. 1988 Oct;38(10):1426–1434. [PubMed] [Google Scholar]
  2. Campbell B. C., Elliott H. L., Hamilton C. A., Reid J. L. Changes in blood pressure, heart rate, and sympathetic activity on abrupt withdrawal of tiamenidine (HOE 440) in essential hypertension. Eur J Clin Pharmacol. 1980 Nov;18(6):449–454. doi: 10.1007/BF00874654. [DOI] [PubMed] [Google Scholar]
  3. Da Prada M., Zürcher Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci. 1976 Oct 15;19(8):1161–1174. doi: 10.1016/0024-3205(76)90251-4. [DOI] [PubMed] [Google Scholar]
  4. Davies D. S., Wing A. M., Reid J. L., Neill D. M., Tippett P., Dollery C. T. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther. 1977 May;21(5):593–601. doi: 10.1002/cpt1977215593. [DOI] [PubMed] [Google Scholar]
  5. Derkx F. H., Tan-Tjiong H. L., Man in 't Veld A. J., Schalekamp M. P., Schalekamp M. A. Activation of inactive plasma renin by plasma and tissue kallikreins. Clin Sci (Lond) 1979 Oct;57(4):351–357. doi: 10.1042/cs0570351. [DOI] [PubMed] [Google Scholar]
  6. Dollery C. T., Davies D. S., Draffan G. H., Dargie H. J., Dean C. R., Reid J. L., Clare R. A., Murray S. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther. 1976 Jan;19(1):11–17. doi: 10.1002/cpt197619111. [DOI] [PubMed] [Google Scholar]
  7. Dollery C. T., Reid J. L. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. Arzneimittelforschung. 1982;32(8A):984–987. [PubMed] [Google Scholar]
  8. Ernsberger P., Giuliano R., Willette R. N., Reis D. J. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther. 1990 Apr;253(1):408–418. [PubMed] [Google Scholar]
  9. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol. 1980 Sep;10(3):189–209. doi: 10.1111/j.1365-2125.1980.tb01745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hossmann V., Maling T. J., Hamilton C. A., Reid J. L., Dollery C. T. Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167–176. doi: 10.1038/clpt.1980.146. [DOI] [PubMed] [Google Scholar]
  11. Johnson B. F., Danylchuk M. A. The relevance of plasma lipid changes with cardiovascular drug therapy. Med Clin North Am. 1989 Mar;73(2):449–473. doi: 10.1016/s0025-7125(16)30682-4. [DOI] [PubMed] [Google Scholar]
  12. Kirch W., Hutt H. J., Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet. 1988 Oct;15(4):245–253. doi: 10.2165/00003088-198815040-00004. [DOI] [PubMed] [Google Scholar]
  13. Kobinger W., Walland A. Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl. Eur J Pharmacol. 1967 Dec;2(3):155–162. doi: 10.1016/0014-2999(67)90080-5. [DOI] [PubMed] [Google Scholar]
  14. Kooner J. S., Peart W. S., Mathias C. J. The haemodynamic and hormonal responses after clonidine occur independently of sedation in essential hypertension. Br J Clin Pharmacol. 1989 Sep;28(3):249–255. doi: 10.1111/j.1365-2125.1989.tb05423.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lardinois C. K., Neuman S. L. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988 Jun;148(6):1280–1288. [PubMed] [Google Scholar]
  16. Lowenthal D. T., Matzek K. M., MacGregor T. R. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet. 1988 May;14(5):287–310. doi: 10.2165/00003088-198814050-00002. [DOI] [PubMed] [Google Scholar]
  17. Michel M. C., Brodde O. E., Schnepel B., Behrendt J., Tschada R., Motulsky H. J., Insel P. A. [3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. Mol Pharmacol. 1989 Mar;35(3):324–330. [PubMed] [Google Scholar]
  18. Michel M. C., Insel P. A. Are there multiple imidazoline binding sites? Trends Pharmacol Sci. 1989 Sep;10(9):342–344. doi: 10.1016/0165-6147(89)90002-3. [DOI] [PubMed] [Google Scholar]
  19. Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol. 1987 Jan;27(1):46–51. doi: 10.1177/009127008702700107. [DOI] [PubMed] [Google Scholar]
  20. Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol. 1984;27(2):147–152. doi: 10.1007/BF00544037. [DOI] [PubMed] [Google Scholar]
  21. Plänitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol. 1986;29(6):645–650. doi: 10.1007/BF00615953. [DOI] [PubMed] [Google Scholar]
  22. Reid J. L. Alpha-adrenergic receptors and blood pressure control. Am J Cardiol. 1986 Mar 28;57(9):6E–12E. doi: 10.1016/0002-9149(86)90716-2. [DOI] [PubMed] [Google Scholar]
  23. Reid J. L. Central alpha 2 receptors and the regulation of blood pressure in humans. J Cardiovasc Pharmacol. 1985;7 (Suppl 8):S45–S50. [PubMed] [Google Scholar]
  24. Reid J. L. The Fourth Lilly Prize Lecture, University of Aberdeen, September 1980. The clinical pharmacology of clonidine and related central antihypertensive agents. Br J Clin Pharmacol. 1981 Sep;12(3):295–302. doi: 10.1111/j.1365-2125.1981.tb01217.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Reid J. L., Wing L. M., Mathias C. J., Frankel H. L., Neill E. The central hypotensive effect of clonidine. Studies in tetraplegic subjects. Clin Pharmacol Ther. 1977 Apr;21(4):375–381. doi: 10.1002/cpt1977214375. [DOI] [PubMed] [Google Scholar]
  26. Schlicker E., Armah B. I., Göthert M. Central presynaptic alpha 2-autoreceptors are involved in the blood pressure-lowering effect of moxonidine. J Cardiovasc Pharmacol. 1990 Jul;16(1):15–22. doi: 10.1097/00005344-199007000-00003. [DOI] [PubMed] [Google Scholar]
  27. Sumner D. J., Meredith P. A., Howie C. A., Elliott H. L. Initial blood pressure as a predictor of the response to antihypertensive therapy. Br J Clin Pharmacol. 1988 Dec;26(6):715–720. doi: 10.1111/j.1365-2125.1988.tb05310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Trenk D., Wagner F., Jähnchen E., Plänitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol. 1987 Dec;27(12):988–993. doi: 10.1002/j.1552-4604.1987.tb05602.x. [DOI] [PubMed] [Google Scholar]
  29. Wing L. M., Reid J. L., Davies D. S., Neill E. A., Tippett P., Dollery C. T. Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol. 1977 Dec 28;12(6):463–469. doi: 10.1007/BF00561067. [DOI] [PubMed] [Google Scholar]
  30. Wing L. M., Reid J. L., Hamilton C. A., Sever P., Davies D. S., Dollery C. T. Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med. 1977 Jul;53(1):45–53. doi: 10.1042/cs0530045. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES